Join Transform 2021 this July 12-16. Register for the AI event of the year.


Biopharm company BioLogix raised $6 million in first-round equity and debt financing from Essex Woodlands Health Ventures and New Science Ventures. The money will be used to continue development of its top cancer-fighting compound, but a second round is already in the works.

So far the Palo Alto, Calif.-based firm has brought in $40 million. It hopes to take enough in its next fund-raising effort by early 2009 to push the drug into clinial testing, setting the bar at $12 to $17 million, reports VentureWire.

Cocurrently, Dale Pfost was tapped to be chief executive, replacing Thomas Glaze who will still serve as chairman. Pfost left the same post at peer company Opko Health.

Past BioLogix investors include Domain Associates, MedImmune Ventures, Northwest Technology Ventures, Skyline Ventures and Takeda Research Investment.

VentureBeat

VentureBeat's mission is to be a digital town square for technical decision-makers to gain knowledge about transformative technology and transact. Our site delivers essential information on data technologies and strategies to guide you as you lead your organizations. We invite you to become a member of our community, to access:
  • up-to-date information on the subjects of interest to you
  • our newsletters
  • gated thought-leader content and discounted access to our prized events, such as Transform 2021: Learn More
  • networking features, and more
Become a member